<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Neurooncol</journal-id>
      <journal-id journal-id-type="iso-abbrev">J. Neurooncol</journal-id>
      <journal-title-group>
        <journal-title>Journal of Neuro-Oncology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0167-594X</issn>
      <issn pub-type="epub">1573-7373</issn>
      <publisher>
        <publisher-name>Springer US</publisher-name>
        <publisher-loc>New York</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26839020</article-id>
      <article-id pub-id-type="pmc">4835516</article-id>
      <article-id pub-id-type="publisher-id">2069</article-id>
      <article-id pub-id-type="doi">10.1007/s11060-016-2069-1</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Clinical Study</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>&#x201C;Comet tail sign&#x201D;: A pitfall of post-gadolinium magnetic resonance imaging findings for metastatic brain tumors</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Mitsuya</surname>
            <given-names>Koichi</given-names>
          </name>
          <address>
            <phone>+81-55-989-5222</phone>
            <email>k.mitsuya@scchr.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nakasu</surname>
            <given-names>Yoko</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Narita</surname>
            <given-names>Yoshitaka</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nakasu</surname>
            <given-names>Satoshi</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ohno</surname>
            <given-names>Makoto</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Miyakita</surname>
            <given-names>Yasuji</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Abe</surname>
            <given-names>Masato</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ito</surname>
            <given-names>Ichiro</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hayashi</surname>
            <given-names>Nakamasa</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Endo</surname>
            <given-names>Masahiro</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <aff id="Aff1"><label/>Division of Neurosurgery, Shizuoka Cancer Center, 1007 Naga-izumi, Shizuoka, 411-8777 Japan </aff>
        <aff id="Aff2"><label/>Division of Pathology, Shizuoka Cancer Center, Shizuoka, Japan </aff>
        <aff id="Aff3"><label/>Division of Diagnostic Radiology, Shizuoka Cancer Center, Shizuoka, Japan </aff>
        <aff id="Aff4"><label/>Division of Neurosurgery, National Cancer Center, Tokyo, Japan </aff>
        <aff id="Aff5"><label/>Division of Neuro-oncology, Kusatsu General Hospital, Shiga, Japan </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>2</day>
        <month>2</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>2</day>
        <month>2</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2016</year>
      </pub-date>
      <volume>127</volume>
      <fpage>589</fpage>
      <lpage>595</lpage>
      <history>
        <date date-type="received">
          <day>22</day>
          <month>7</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>26</day>
          <month>1</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2016</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>A highly enhanced cap attached to the surface of metastatic tumors in the brain parenchyma is occasionally encountered on magnetic resonance (MR) images. This atypical enhanced cap tends to occur in severe peritumoral edema and may produce the characteristic bulge of a metastatic mass lesion termed the &#x201C;comet tail sign&#x201D; (CTS). The purpose of this study was to demonstrate the features of the CTS using MR imaging and pathological findings, and to clarify its clinical relevance. We selected 21 consecutive cases of newly diagnosed metastases from MR imaging studies that demonstrated the CTS; all had diffuse peritumoral edema. The MR T2-weighted images showed similarly homogenous and high intensity signals in both the tail and peritumoral edema. Fourteen of the 21 patients underwent surgical resection of their tumors, and 12 tails were separately removed for pathological examination, no tumor cells which revealed. We speculate that the CTS does not contain neoplastic tissues but is observed as a result of the leakage of contrast medium from the tumor body into the interstitial space of the white matter. Although CTS is a peculiar and uncommon enhancement pattern, it has clinical significance in determining the extent of the margin for invasive local treatments, such as surgical resection or stereotactic radiotherapy; this is particularly true in and near the eloquent areas.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Atypical enhancement pattern</kwd>
        <kwd>Extravasation</kwd>
        <kwd>Gadolinium</kwd>
        <kwd>Magnetic resonance imaging</kwd>
        <kwd>Metastatic brain tumor</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer Science+Business Media New York 2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p>Metastatic brain tumors occur in 8.5&#x2013;40&#xA0;% of patients with systemic cancers [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Recent advances in the systemic management of cancer patients and novel imaging techniques have led to an increase in the number of long-term survivors with brain metastases [<xref ref-type="bibr" rid="CR3">3</xref>]. Magnetic resonance (MR) imaging is the most reliable diagnostic technique for metastatic brain tumors [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Typical MR images show tumor mass lesions of well-circumscribed enhancement; they have isointense or high-intensity signals on T2-weighted images and low-intensity signals on T1-weighted images [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. These lesions are surrounded by areas of peritumoral edema of various sizes [<xref ref-type="bibr" rid="CR8">8</xref>].</p>
      <p>We found a highly enhanced peripheral area that was attached to an enhanced main tumor mass in the brain parenchyma. This peripheral enhancement had a constant pattern of intense and homogenous signals. It appeared to be budding-off from the main tumor mass, which we recognized as a unique feature among brain metastases. A series of cases with this characteristic enhancing pattern were compiled. We termed this pattern the &#x201C;comet tail sign&#x201D; (CTS) because of its resemblance to a shooting star with a tail.</p>
      <p>The purpose of the current study was to retrospectively demonstrate the MR features of CTS and to clarify its clinical relevance in our patient series.</p>
      <sec id="Sec2">
        <title>Patients and methods</title>
        <p>This study involved a retrospective review of 21 patients who exhibited the characteristic caps of intense peripheral enhancement that were attached to the surface of metastatic brain tumors. MR imaging was performed using a 1.5T MR imaging system (Intera: Philips Healthcare, Best, The Netherlands). From all of the 21 patients, unenhanced spin-echo T1-weighted axial images, fast spin-echo T2-weighted axial images, and contrast-enhanced 3D-gradient echo T1WIs were obtained. The MR imaging parameters used were as follows: repetition time (TR)/echo time (TE), 350&#x2013;600/12&#xA0;ms; number of excitations (NEX), 1; matrix, 320&#xA0;&#xD7;&#xA0;225 for T1WI and TR/TE of 4500/90&#xA0;ms; flip angle, 15&#xB0;; NEX, 1, matrix, 256&#xA0;&#xD7;&#xA0;205 for T2WI. The other parameters were: 5-mm section thickness; 0.5-mm gap; and 230-mm field of view (FOV). For contrast-enhanced T1W images, we routinely commenced reference imaging at 1&#xA0;min after a single intravenous injection of gadopentetate dimeglumine (Magnevist: Bayer Health Care Pharmaceuticals, Wayne, NJ, USA) at a dose of 0.2&#xA0;mL/kg. It took approximately 40&#xA0;s to complete the reference imaging, and we proceeded to sagittal, coronal, and axial scans in due order. It took approximately 2&#xA0;min to obtain images of each plane. Consequently, our routine contrast imaging started 2&#xA0;min after the injection of contrast material, and finished after an interval of approximately 6&#xA0;min. The reported cases were consistently examined using this protocol. The parameters for contrast-enhanced T1WI were: TR/TE, 14/4.6&#xA0;ms; flip angle, 15&#xB0;; NEX, 1; matrix, 256&#xA0;&#xD7;&#xA0;179; section thickness, 4&#xA0;mm; gap, 2&#xA0;mm; and FOV, 230&#xA0;mm.</p>
        <p>All of the 21 patients had characteristic comet-shaped main masses and tails in the brain on post-contrast MR images. All showed increased T2WI signals from the tails in diffuse perifocal edema. Fourteen patients underwent surgical removal of the masses, and 12 of them underwent biopsies or resection of the tails. Two representative cases are described below with pathological confirmation regarding the tails.</p>
      </sec>
    </sec>
    <sec id="Sec3">
      <title>Results</title>
      <p>Twenty-one patients who had metastatic brain tumors with CTS were observed at our hospital from August 2008 to March 2015 (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). All of these patients presented with newly diagnosed metastases in the brain. Median patient age was 66 (range, 44&#x2013;81) years with a female-to-male ratio of 3:18. Monitoring of samples in one of the institutes indicated that the incidence of CTS was 3&#xA0;% (10 patients out of 329 with newly diagnosed metastatic brain tumors over 1&#xA0;year).<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>Clinical and pathological characteristics of patients with comet tail sign</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Case</th><th align="left">Age</th><th align="left">Sex</th><th align="left">Primary</th><th align="left">Pathology</th><th align="left">Location</th><th align="left">Tumor volume (ml)</th><th align="left">Edema volume (ml)</th><th align="left">Edema index</th><th align="left">Comet tail MR; T2 intensity</th><th align="left">Treatment</th><th align="left">Comet tail; pathology</th><th align="left">Remnant tail; post Op</th><th align="left">Remnant tail; follow-up</th><th align="left">Local control</th></tr></thead><tbody><tr><td align="left">1</td><td char="." align="char">72</td><td align="left">M</td><td align="left">Lung</td><td align="left">ad</td><td align="left">Occipital</td><td align="left">20</td><td align="left">285.7</td><td align="left">14.3</td><td align="left">High</td><td align="left">Op&#xA0;+&#xA0;RT</td><td align="left">No tumor cell, MVP</td><td align="left">(+)</td><td align="left">Disapeared</td><td align="left">No rec</td></tr><tr><td align="left">2</td><td char="." align="char">57</td><td align="left">M</td><td align="left">Lung</td><td align="left">pleo</td><td align="left">Parietal</td><td align="left">23</td><td align="left">200.2</td><td align="left">8.7</td><td align="left">High</td><td align="left">Op&#xA0;+&#xA0;RT</td><td align="left">No tumor cell, MVP</td><td align="left">(+)</td><td align="left">Disapeared</td><td align="left">No rec</td></tr><tr><td align="left">3</td><td char="." align="char">64</td><td align="left">M</td><td align="left">Lung</td><td align="left">large</td><td align="left">Frontal</td><td align="left">7.5</td><td align="left">146.9</td><td align="left">19.6</td><td align="left">High</td><td align="left">Op&#xA0;+&#xA0;RT</td><td align="left">No tumor cell, MVP</td><td align="left">None</td><td align="left">None</td><td align="left">No rec</td></tr><tr><td align="left">4</td><td char="." align="char">60</td><td align="left">M</td><td align="left">Colon</td><td align="left">ad</td><td align="left">Occipital</td><td align="left">35.5</td><td align="left">142.1</td><td align="left">4</td><td align="left">High-iso</td><td align="left">Op&#xA0;+&#xA0;RT</td><td align="left">No tumor cell, MVP</td><td align="left">(+)</td><td align="left">Disapeared</td><td align="left">No rec</td></tr><tr><td align="left">5</td><td char="." align="char">61</td><td align="left">M</td><td align="left">Pharyngs</td><td align="left">sq</td><td align="left">Parietal</td><td align="left">7.1</td><td align="left">85.7</td><td align="left">12.1</td><td align="left">High</td><td align="left">Op&#xA0;+&#xA0;RT</td><td align="left">No tumor cell, MVP</td><td align="left">(+)</td><td align="left">Disapeared</td><td align="left">No rec</td></tr><tr><td align="left">6</td><td char="." align="char">79</td><td align="left">M</td><td align="left">Esophagus</td><td align="left">sq</td><td align="left">Occipital</td><td align="left">29.8</td><td align="left">175.9</td><td align="left">5.9</td><td align="left">High</td><td align="left">Op&#xA0;+&#xA0;RT</td><td align="left">No tumor cell, MVP</td><td align="left">None</td><td align="left">None</td><td align="left">No rec</td></tr><tr><td align="left">7</td><td char="." align="char">81</td><td align="left">M</td><td align="left">Lung</td><td align="left">ad</td><td align="left">Temporal</td><td align="left">41.5</td><td align="left">265</td><td align="left">6.4</td><td align="left">High</td><td align="left">Op&#xA0;+&#xA0;RT</td><td align="left">No tumor cell, MVP</td><td align="left">none</td><td align="left">None</td><td align="left">No rec</td></tr><tr><td align="left">8</td><td char="." align="char">77</td><td align="left">F</td><td align="left">Uterus body</td><td align="left">cs</td><td align="left">Frontal</td><td align="left">50</td><td align="left">226.8</td><td align="left">4.5</td><td align="left">High</td><td align="left">Op&#xA0;+&#xA0;RT</td><td align="left">No tumor cell, MVP</td><td align="left">(+)</td><td align="left">Disapeared</td><td align="left">No rec</td></tr><tr><td align="left">9</td><td char="." align="char">70</td><td align="left">M</td><td align="left">Gastric</td><td align="left">ad</td><td align="left">Cerebellar</td><td align="left">57.9</td><td align="left">83.7</td><td align="left">1.4</td><td align="left">High</td><td align="left">Op&#xA0;+&#xA0;RT</td><td align="left">No tumor cell, MVP</td><td align="left">None</td><td align="left">None</td><td align="left">No rec</td></tr><tr><td align="left">10</td><td char="." align="char">60</td><td align="left">M</td><td align="left">Lung</td><td align="left">ad</td><td align="left">Frontal</td><td align="left">47.5</td><td align="left">185.5</td><td align="left">3.9</td><td align="left">High</td><td align="left">Op&#xA0;+&#xA0;RT</td><td align="left">No tumor cell, MVP</td><td align="left">(+)</td><td align="left">Disapeared</td><td align="left">No rec</td></tr><tr><td align="left">11</td><td char="." align="char">61</td><td align="left">F</td><td align="left">Breast</td><td align="left">ad</td><td align="left">Frontal</td><td align="left">29.7</td><td align="left">373</td><td align="left">12.6</td><td align="left">High</td><td align="left">Op</td><td align="left">No tumor cell, MVP</td><td align="left">(+)</td><td align="left">Disapeared</td><td align="left">no rec</td></tr><tr><td align="left">12</td><td char="." align="char">60</td><td align="left">M</td><td align="left">Gastric</td><td align="left">ad</td><td align="left">Frontal</td><td align="left">15.6</td><td align="left">219.2</td><td align="left">14.1</td><td align="left">High</td><td align="left">Op</td><td align="left">No tumor cell, MVP</td><td align="left">None</td><td align="left">None</td><td align="left">No rec</td></tr><tr><td align="left">13</td><td char="." align="char">62</td><td align="left">M</td><td align="left">Lung</td><td align="left">ad</td><td align="left">Cerebellar</td><td align="left">12.8</td><td align="left">99.6</td><td align="left">7.8</td><td align="left">High</td><td align="left">Op&#xA0;+&#xA0;SRS</td><td align="left">N.A.</td><td align="left">(+)</td><td align="left">Disapeared</td><td align="left">No rec</td></tr><tr><td align="left">14</td><td char="." align="char">76</td><td align="left">M</td><td align="left">Colon</td><td align="left">ad</td><td align="left">Occipital</td><td align="left">22.2</td><td align="left">159.3</td><td align="left">7.2</td><td align="left">High-iso</td><td align="left">Op</td><td align="left">N.A.</td><td align="left">(+)</td><td align="left">Disapeared</td><td align="left">Main mass rec</td></tr><tr><td align="left">15</td><td char="." align="char">78</td><td align="left">M</td><td align="left">Gastric</td><td align="left">ad</td><td align="left">Frontal</td><td align="left">4.1</td><td align="left">150.2</td><td align="left">37.5</td><td align="left">High</td><td align="left">SRT</td><td align="left">/</td><td align="left">/</td><td align="left">/</td><td align="left">No rec</td></tr><tr><td align="left">16</td><td char="." align="char">70</td><td align="left">M</td><td align="left">Lung</td><td align="left">sq</td><td align="left">Occipital</td><td align="left">5.4</td><td align="left">117.5</td><td align="left">23.5</td><td align="left">High</td><td align="left">SRT</td><td align="left">/</td><td align="left">/</td><td align="left">/</td><td align="left">Main mass rec</td></tr><tr><td align="left">17</td><td char="." align="char">54</td><td align="left">M</td><td align="left">Lung</td><td align="left">ad</td><td align="left">Temporal</td><td align="left">3.8</td><td align="left">110.5</td><td align="left">29.1</td><td align="left">High</td><td align="left">SRT</td><td align="left">/</td><td align="left">/</td><td align="left">/</td><td align="left">Radiation necrosis</td></tr><tr><td align="left">18</td><td char="." align="char">78</td><td align="left">M</td><td align="left">Colon</td><td align="left">sd</td><td align="left">Frontal</td><td align="left">3.4</td><td align="left">84</td><td align="left">24.7</td><td align="left">High</td><td align="left">SRT</td><td align="left">/</td><td align="left">/</td><td align="left">/</td><td align="left">No rec</td></tr><tr><td align="left">19</td><td char="." align="char">44</td><td align="left">M</td><td align="left">Lung</td><td align="left">ad</td><td align="left">Parietal</td><td align="left">17.1</td><td align="left">107.7</td><td align="left">6.3</td><td align="left">High</td><td align="left">WBRT</td><td align="left">/</td><td align="left">/</td><td align="left">/</td><td align="left">No rec</td></tr><tr><td align="left">20</td><td char="." align="char">64</td><td align="left">M</td><td align="left">Lung</td><td align="left">small</td><td align="left">Cerebellar</td><td align="left">15.6</td><td align="left">78.4</td><td align="left">5</td><td align="left">High</td><td align="left">WBRT</td><td align="left">/</td><td align="left">/</td><td align="left">/</td><td align="left">No rec</td></tr><tr><td align="left">21</td><td char="." align="char">63</td><td align="left">F</td><td align="left">Lung</td><td align="left">ad</td><td align="left">Temporal</td><td align="left">2.4</td><td align="left">85.8</td><td align="left">40</td><td align="left">High</td><td align="left">WBRT</td><td align="left">/</td><td align="left">/</td><td align="left">/</td><td align="left">No rec</td></tr></tbody></table><table-wrap-foot><p>
<italic>ad</italic> adenocarcinoma, <italic>pleo</italic> pleomorphic carcinoma, <italic>large</italic> large-cell carcinoma, <italic>small</italic> small-cell carcinoma, <italic>sq</italic> squamous-cell carcinoma, <italic>cs</italic> carcinosarcoma, <italic>rec</italic> recurrence, <italic>MVP microvascular proliferation, N.A</italic>. not analyzed, <italic>OP</italic> operation, <italic>RT</italic> Radiotherapy, <italic>SRS</italic> stereotactic radiosurgery,<italic>SRT</italic> stereotactic radiotherapy<italic>, WBRT</italic> whole brain radiotherapy</p></table-wrap-foot></table-wrap></p>
      <p>A majority of the patients presented with lung cancer (11 cases [52&#xA0;%]); seven had adenocarcinoma, and one each had squamous cell carcinoma, small-cell carcinoma, large-cell carcinoma, and pleomorphic carcinoma. The remaining patients had gastric cancer (3 cases) and colorectal cancer (3 cases); in addition, there was one case each of breast, pharyngeal, esophageal and uterus body cancer.</p>
      <p>Post-gadolinium T1WI demonstrated more intense and homogenous enhancement in the tail than in the main body (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>). T2WI revealed that the main body of the tumor had a signal that ranged from low-intensity to isointensity; however, the tail of the CTS had a high-intensity signal buried in peritumoral diffuse edema (Figs.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>b and <xref rid="Fig2" ref-type="fig">2</xref>b). When these metastatic brain tumors with CTS were situated near the ventricle, the tails always pointed towards the ventricle; more specifically, they pointed towards the anterior horn (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>a) and the posterior horn (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>b) of the lateral ventricle, and towards the fourth ventricle (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>c). The tail of the CTS disappeared concurrently with the decrease in perifocal edema in a single patient after administration of dexamethasone for 1&#xA0;week (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>
<bold>a</bold> T1-contrast enhancement (CE) image demonstrating the comet tail sign with characteristic perilesional intense contrast enhancement (<italic>white arrow</italic>) in the <italic>right</italic> parietal region. <bold>b</bold> T2-weighted images demonstrating diffuse brain edema. The tail of the comet has a high-intensity signal equal to that of the perifocal edema (<italic>black arrow</italic>). The main body is surrounded by sulci, and the tail is located at the neck of the gyrus. <bold>c</bold> 2-Deoxy-2[F-18]fluoro-<sc>d</sc>-glucose-positron emission tomography image showing no accumulation of tracer in the tail of the comet tail sign (CTS). <bold>d</bold> Photomicrographs of stained tissue sections showing a pleomorphic carcinoma in the main mass (<italic>lower column</italic>), but no neoplastic cells in the tail region (<italic>upper column</italic>) (hematoxylin and eosin stain). <bold>e</bold> The tumor and a part of the tail were resected separately. Postoperative MR image showing the residual tail of the CTS (postoperative day 2). <bold>f</bold> This residual tail of CTS had disappeared on follow-up MR images at 3&#xA0;months after surgery</p></caption><graphic xlink:href="11060_2016_2069_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig.&#xA0;2</label><caption><p>
<bold>a</bold> T1-CE image showing a <italic>left</italic> frontal mass with a CTS (<italic>white arrow</italic>). <bold>b</bold> T2-weighted image demonstrating severely diffuse brain edema. The tail of the comet has a high-intensity signal equivalent to the perifocal edema (<italic>white</italic>
<bold>a</bold> and <italic>black</italic>
<bold>b</bold>
<italic>arrows</italic>). The tail of the comet protrudes into the anterior horn of the lateral ventricle. <bold>c</bold> Methionine-positron emission tomography images showing no accumulation of tracer in the tail of the CTS. <bold>d</bold> Intraoperative T1-CE showing that the main body was removed. The remnant of the tail was removed after imaging. <bold>e</bold> Photomicrograph showing microvascular proliferation, but no neoplastic cells in the CTS (hematoxylin and eosin stain). <bold>f</bold> Photomicrograph showing an adenocarcinoma (<italic>breast cancer</italic>) in the main lesion</p></caption><graphic xlink:href="11060_2016_2069_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig.&#xA0;3</label><caption><p>T1-CE images demonstrating masses with the CTS in three different patients. The tails protrude into the anterior (<bold>a</bold>) and posterior (<bold>b</bold>) horns of the lateral ventricle, and into the forth ventricle (<bold>c</bold>)</p></caption><graphic xlink:href="11060_2016_2069_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Fig.&#xA0;4</label><caption><p>
<bold>a</bold> MR T1-CE showing the CTS in the <italic>right</italic> frontal metastatic brain tumor of a patient with lung cancer. <bold>b</bold> MR T1-CE image showing that the tail of the CTS had disappeared after administration of corticosteroids</p></caption><graphic xlink:href="11060_2016_2069_Fig4_HTML" id="MO4"/></fig></p>
      <p>Fourteen patients underwent surgical resection, among which 12 involved both the main masses and the tails. Pathological examination of the tails of the CTS revealed edema and micro-vascular proliferation, but no neoplastic cells (Figs.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>d and <xref rid="Fig2" ref-type="fig">2</xref>e). Nine patients had remnant comet tails on MR images at 2&#xA0;days after surgery (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). Considered overall, follow-up MR images demonstrated the disappearance of the tails regardless of whether patients had received adjuvant therapies a few months after surgery.</p>
      <p>Among the seven patients who did not undergo surgical resection, four underwent stereotactic radiotherapy targeted exclusively at the main masses. The tails of the CTS disappeared and never recurred after stereotactic radiotherapy. They also disappeared and did not recur in the other three patients who underwent whole brain radiation therapy (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>).</p>
      <sec id="Sec4">
        <title>Case 1</title>
        <p>A 57-year-old man presented with a week-long history of left hemiparesis and left spatial agnosia. MR images revealed a single brain tumor that was 45&#xA0;mm in diameter, with a CTS and diffuse brain edema in the right parietal lobe (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>a, b). Systemic examination revealed lung cancer. Because the tail showed a high-intensity signal on T2WI (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>a, b) similar to the peritumoral edema, we suspected that it consisted of tissues that differed from the main body of the tumor. Using 2-deoxy-2[F-18]fluoro -<sc>d</sc>-glucose positron emission tomography, it was demonstrated that there was no accumulation of tracer in the tail of the CTS (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>c). The main mass and a part of the tail were resected separately. Pathological examination revealed a pleomorphic carcinoma in the main mass (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>d lower column), but no neoplastic cells in the tail region (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>d upper column). Postoperative MR images demonstrated a residual tail of the CTS (postoperative day 2; Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>e), but this had disappeared on the follow-up MR image at 3&#xA0;months after surgery (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>f).</p>
      </sec>
      <sec id="Sec5">
        <title>Case 2</title>
        <p>A 61-year-old woman presented with urinary incontinence. She had undergone breast cancer surgery 15&#xA0;years previously, followed by six courses of postoperative chemotherapy, and tamoxifen therapy for 2&#xA0;years. MR images revealed a large single mass of 43&#xA0;mm in diameter in the left frontal lobe. The tail of the CTS extended towards the anterior horn of the lateral ventricle (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>a) in diffuse edema (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>b).</p>
        <p>Methionine-positron emission tomography images demonstrated no accumulation of tracer in the tail of the CTS (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>c). After complete removal of the tumor, the residual tail of the CTS was resected separately under the guidance of intraoperative MR imaging (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>d). Pathological examination revealed an adenocarcinoma in the main mass (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>f), and microvascular proliferation in the tail region of the CTS, but no neoplastic cells in the white matter gliosis (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>e).</p>
      </sec>
    </sec>
    <sec id="Sec6">
      <title>Discussion</title>
      <p>In the present study, we present the findings from 21 patients with newly diagnosed metastatic brain tumors who had a peculiar enhancement feature on MR images termed the CTS. The CTS showed exhibited specific features on T2-WI and post-gadolinium T1WI. Although the presence of a CTS is not a common finding for metastatic brain tumors, it is a reliable marker; it can be a serious pitfall when the margins of metastatic tumors are delineated, as revealed by pathological examination in our study.</p>
      <p>The CTS consists of a main lesion and a tail. The common features of CTS observed in this study can be summarized as follows. First, it had the appearance of an enhanced mass consisting of two components attached to each other. The tail exhibited more intense and homogenous enhancement than the main lesion on post-gadolinium T1WI. Second, the tail had the same signal intensity as the peritumoral edema; however, the main lesion showed isointensity or low-signal intensity on T2WI as is generally found. Third, the tail always extended towards the deep white matter and ventricles. These findings suggest that the CTS is composed of tissue that differs from the main neoplastic lesion.</p>
      <p>In the present study, all cases exhibited severe peritumoral edema on T2WI. They had higher edema indexes than those previously reported for brain metastases, with a median value of 8.7 (range, 1.4&#x2013;40.0; 95&#xA0;% confidence interval [CI], 8.6&#x2013;18.9) in our CTS cases, while the median value was 3.3 (range, 1.0&#x2013;9.1; 95&#xA0;% CI 2.8&#x2013;5.0) in previously reported cases of brain metastases [<xref ref-type="bibr" rid="CR8">8</xref>]. This severe edema may be related to one of the causes of the CTS. Our hypothesis is that chemical substances that were extravasated from the tumor body could have been retained and concentrated in the local white matter; this occurred when the white matter was anatomically surrounded by sulci or the brain surface, and connected only towards the deep white matter and the periventricular region [<xref ref-type="bibr" rid="CR9">9</xref>]. These chemical substances may include vasodilators and contrast medium. In the current study, the tail of the CTS disappeared along with perifocal edema after the administration of sufficient corticosteroids (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>). Considered overall, we suggest that the CTS may represent extravasation of contrast medium from the blood-tumor barrier and its retention within the interstitial space of white matter outside the tumor [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>].</p>
      <p>The CTS is of clinical importance regarding the local treatment of brain metastasis, particularly in the eloquent areas, although it is an uncommon finding. In all of the 12 patients who underwent biopsy or resection of the tails, pathological examination did not reveal tumor cells or microvascular proliferation in the edematous gliotic white matter. For surgical resection, total removal of the CTS is not required, although biopsy may be needed for confirmation of non-neoplastic conditions. Regarding the planning of radiosurgery, the CTS poses a challenge in relation to tumor delineation. Its presence may also indicate an increased risk of late radiation effects in the brain as a result of excessive radiation dose, or of poor tumor control as a result of the delivery of an insufficient radiation dose to the tail region.</p>
      <p>Brain metastasis accompanied by CTS may possess different biological features to those of typical brain metastasis. All of the main lesions in our series were situated in the superficial subcortical layers and were attached to tails pointing towards the deep or periventricular white matter. Pathological examination revealed glomeruloid microvascular proliferation in the tails of the CTS in several cases, as previously reported [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. This hypervascularity may be another possible cause of the CTS.</p>
      <p>A limitation of the present study was its retrospective nature. Of the 21 patients who exhibited the CTS detected during routine MR examination for brain metastasis, only 12 underwent pathological confirmation concerning the tail region. The mechanism behind the formation of the attached tail may include compound phenomena. The natural history, surgical and radiologic-pathologic correlation, and treatment outcomes should be analyzed in a larger cohort of patients.</p>
    </sec>
    <sec id="Sec7">
      <title>Conclusion</title>
      <p>We reported on the MR features of an atypical perilesional contrast enhancement in metastatic brain tumors termed the &#x201C;comet tail sign&#x201D; and abbreviated as CTS. The CTS may represent a pitfall in the assessment of metastatic brain tumors that demonstrate enhancement of potentially non-neoplastic tissue. Although it is an uncommon MR finding, the CTS has clinical significance in treatment planning regarding the extent of invasive local treatment, such as surgical resection or stereotactic radiotherapy.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>We are grateful to Mr. Kensei Shirata and Ms. Reiko Suzuki for their assistance in editing the manuscript.</p>
    </ack>
    <notes notes-type="conflict-interest">
      <title>Compliance with ethical standards</title>
      <sec id="FPar1">
        <title>Conflict of interest</title>
        <p>The authors report no potential conflicts of interest concerning the materials or methods used in this study or the findings presented.</p>
      </sec>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Hojo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hirano</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Takakura</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sano</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hojo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hirano</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Pathology of metastases affecting the central nervous system</article-title>
          <source>Metastatic tumors of the central nervous system</source>
          <year>1982</year>
          <publisher-loc>Tokyo</publisher-loc>
          <publisher-name>Igaku-shoin</publisher-name>
          <fpage>5</fpage>
          <lpage>111</lpage>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barnholtz-Sloan</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Sloan</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Vengoechea</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dignam</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Vogelbaum</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Sperduto</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Mehta</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Machtay</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kattan</surname>
              <given-names>MW</given-names>
            </name>
          </person-group>
          <article-title>A nomogram for individualized estimation of survival among patients with brain metastasis</article-title>
          <source>Neuro Oncol</source>
          <year>2012</year>
          <volume>14</volume>
          <fpage>910</fpage>
          <lpage>918</lpage>
          <pub-id pub-id-type="doi">10.1093/neuonc/nos087</pub-id>
          <pub-id pub-id-type="pmid">22544733</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Owonikoko</surname>
              <given-names>TK</given-names>
            </name>
            <name>
              <surname>Arbiser</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zelnak</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Shu</surname>
              <given-names>HK</given-names>
            </name>
            <name>
              <surname>Shim</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Robin</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Kalkanis</surname>
              <given-names>SN</given-names>
            </name>
            <name>
              <surname>Whitsett</surname>
              <given-names>TG</given-names>
            </name>
            <name>
              <surname>Salhia</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Tran</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Ryken</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Egan</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Olson</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
          <article-title>Current approaches to the treatment of metastatic brain tumors</article-title>
          <source>Nat Rev Clin Oncol</source>
          <year>2014</year>
          <volume>11</volume>
          <fpage>203</fpage>
          <lpage>222</lpage>
          <pub-id pub-id-type="doi">10.1038/nrclinonc.2014.25</pub-id>
          <pub-id pub-id-type="pmid">24569448</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sze</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Milano</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Heier</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Detection of brain metastases: comparison of contrast enhanced MR with unenhanced MR and enhanced CT</article-title>
          <source>AJNR Am J Neuroradiol</source>
          <year>1990</year>
          <volume>11</volume>
          <fpage>785</fpage>
          <lpage>791</lpage>
          <pub-id pub-id-type="pmid">2114769</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schellinger</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Meinck</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Thron</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Diagnostic accuracy of MRI compared to CCT in patients with brain metastases</article-title>
          <source>J Neurooncol</source>
          <year>1999</year>
          <volume>44</volume>
          <fpage>275</fpage>
          <lpage>281</lpage>
          <pub-id pub-id-type="doi">10.1023/A:1006308808769</pub-id>
          <pub-id pub-id-type="pmid">10720207</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Smirniotopoulos</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Rushing</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Rees</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Schroeder</surname>
              <given-names>JW</given-names>
            </name>
          </person-group>
          <article-title>Patterns of contrast enhancement in the brain and meninges</article-title>
          <source>Radiographics</source>
          <year>2007</year>
          <volume>27</volume>
          <fpage>525</fpage>
          <lpage>551</lpage>
          <pub-id pub-id-type="doi">10.1148/rg.272065155</pub-id>
          <pub-id pub-id-type="pmid">17374867</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Faehndrich</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Weidauer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pilatus</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Oszvald</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zanella</surname>
              <given-names>FE</given-names>
            </name>
            <name>
              <surname>Hattingen</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Neuroradiological viewpoint on the diagnostics of space-occupying brain lesions</article-title>
          <source>Clin Neuroradiol</source>
          <year>2011</year>
          <volume>21</volume>
          <fpage>123</fpage>
          <lpage>139</lpage>
          <pub-id pub-id-type="doi">10.1007/s00062-011-0073-6</pub-id>
          <pub-id pub-id-type="pmid">21538040</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Strugar</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rothbart</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Harrington</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Criscuolo</surname>
              <given-names>GR</given-names>
            </name>
          </person-group>
          <article-title>Vascular permeability factor in brain metastases: correlation with vasogenic brain edema and tumor angiogenesis</article-title>
          <source>J Neurosurg</source>
          <year>1994</year>
          <volume>81</volume>
          <fpage>560</fpage>
          <lpage>566</lpage>
          <pub-id pub-id-type="doi">10.3171/jns.1994.81.4.0560</pub-id>
          <pub-id pub-id-type="pmid">7523634</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Spanberger</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Berghoff</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Dinhof</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ilhan-Mutlu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Magerle</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hutterer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pichler</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>W&#xF6;hrer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hackl</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Widhalm</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hainfellner</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Dieckmann</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Marosi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Birner</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Prayer</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Preusser</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases</article-title>
          <source>Clin Exp Metastasis</source>
          <year>2013</year>
          <volume>30</volume>
          <fpage>357</fpage>
          <lpage>368</lpage>
          <pub-id pub-id-type="doi">10.1007/s10585-012-9542-9</pub-id>
          <pub-id pub-id-type="pmid">23076770</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Andersen</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Jensen</surname>
              <given-names>FT</given-names>
            </name>
          </person-group>
          <article-title>Differences in blood-tumour-barrier leakage of human intracranial tumours: quantitative monitoring of vasogenic oedema and its response to glucocorticoid treatment</article-title>
          <source>Acta Neurochir (Wien)</source>
          <year>1998</year>
          <volume>140</volume>
          <fpage>919</fpage>
          <lpage>924</lpage>
          <pub-id pub-id-type="doi">10.1007/s007010050194</pub-id>
          <pub-id pub-id-type="pmid">9842429</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bruce</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Criscuolo</surname>
              <given-names>GR</given-names>
            </name>
            <name>
              <surname>Merrill</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Moquin</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Blacklock</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Oldfield</surname>
              <given-names>EH</given-names>
            </name>
          </person-group>
          <article-title>Vascular permeability induced by protein product of malignant brain tumors: inhibition by dexamethasone</article-title>
          <source>J Neurosurg</source>
          <year>1987</year>
          <volume>67</volume>
          <fpage>880</fpage>
          <lpage>884</lpage>
          <pub-id pub-id-type="doi">10.3171/jns.1987.67.6.0880</pub-id>
          <pub-id pub-id-type="pmid">3681425</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arai</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kashihara</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kaizaki</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Enhancing gliotic cyst wall with microvascular proliferation adjacent to a meningioma</article-title>
          <source>J Clin Neurosci</source>
          <year>2006</year>
          <volume>13</volume>
          <fpage>136</fpage>
          <lpage>139</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jocn.2005.02.015</pub-id>
          <pub-id pub-id-type="pmid">16410217</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Singh</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Oevermann</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vandevelde</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Doherr</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Henke</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gorgas</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Contrast media enhancement of intracranial lesions in magnetic resonance imaging does not reflect histopathologic findings consistently</article-title>
          <source>Vet Radiol Ultrasound</source>
          <year>2011</year>
          <volume>52</volume>
          <fpage>619</fpage>
          <lpage>626</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1740-8261.2011.01848.x</pub-id>
          <pub-id pub-id-type="pmid">21777330</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
